HK1195552A1 - 作為 抑制劑的吡咯並三嗪酮衍生物 - Google Patents
作為 抑制劑的吡咯並三嗪酮衍生物Info
- Publication number
- HK1195552A1 HK1195552A1 HK14108933.7A HK14108933A HK1195552A1 HK 1195552 A1 HK1195552 A1 HK 1195552A1 HK 14108933 A HK14108933 A HK 14108933A HK 1195552 A1 HK1195552 A1 HK 1195552A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pi3k
- inhibitors
- pyrrolotriazinone derivatives
- pyrrolotriazinone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11382124A EP2518070A1 (en) | 2011-04-29 | 2011-04-29 | Pyrrolotriazinone derivatives as PI3K inhibitors |
US201161502550P | 2011-06-29 | 2011-06-29 | |
PCT/EP2012/057671 WO2012146666A1 (en) | 2011-04-29 | 2012-04-26 | Pyrrolotriazinone derivatives as pi3k inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1195552A1 true HK1195552A1 (zh) | 2014-11-14 |
Family
ID=44484054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14108933.7A HK1195552A1 (zh) | 2011-04-29 | 2014-09-03 | 作為 抑制劑的吡咯並三嗪酮衍生物 |
Country Status (36)
Country | Link |
---|---|
US (1) | US9340547B2 (zh) |
EP (2) | EP2518070A1 (zh) |
JP (1) | JP5903160B2 (zh) |
KR (1) | KR20140021622A (zh) |
CN (1) | CN103649089B (zh) |
AR (1) | AR086144A1 (zh) |
AU (1) | AU2012247491B2 (zh) |
BR (1) | BR112013023876A2 (zh) |
CA (1) | CA2826197A1 (zh) |
CL (1) | CL2013003073A1 (zh) |
CO (1) | CO6801747A2 (zh) |
CR (1) | CR20130543A (zh) |
CY (1) | CY1116871T1 (zh) |
DK (1) | DK2702061T3 (zh) |
EA (1) | EA024350B1 (zh) |
ES (1) | ES2545853T3 (zh) |
GT (1) | GT201300266A (zh) |
HK (1) | HK1195552A1 (zh) |
HR (1) | HRP20151153T1 (zh) |
HU (1) | HUE026041T2 (zh) |
IL (1) | IL227764A (zh) |
ME (1) | ME02210B (zh) |
MX (1) | MX336214B (zh) |
MY (1) | MY171553A (zh) |
PE (1) | PE20141193A1 (zh) |
PL (1) | PL2702061T3 (zh) |
PT (1) | PT2702061E (zh) |
RS (1) | RS54270B1 (zh) |
SG (1) | SG194084A1 (zh) |
SI (1) | SI2702061T1 (zh) |
SM (1) | SMT201500270B (zh) |
TW (2) | TWI535720B (zh) |
UA (1) | UA111197C2 (zh) |
UY (1) | UY34051A (zh) |
WO (1) | WO2012146666A1 (zh) |
ZA (1) | ZA201305612B (zh) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
WO2014060432A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
KR20210010958A (ko) * | 2012-11-08 | 2021-01-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
CA2891013A1 (en) | 2012-11-16 | 2014-05-22 | Abdelghani Abe Achab | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
WO2014082230A1 (zh) * | 2012-11-28 | 2014-06-05 | 上海希迈医药科技有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用 |
WO2014087208A2 (en) * | 2012-12-06 | 2014-06-12 | Enaltec Labs Pvt. Ltd. | A process of preparing alcaftadine |
PT2941426T (pt) | 2012-12-21 | 2018-07-18 | Gilead Calistoga Llc | Quinazolinonas aminoalquis de pirimidina substituída como inibidores de fosfatidilinositol 3-quinase |
ES2685568T3 (es) | 2012-12-21 | 2018-10-10 | Gilead Calistoga Llc | Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa |
TW201446767A (zh) * | 2013-02-15 | 2014-12-16 | Almirall Sa | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 |
SI3008053T1 (en) | 2013-06-14 | 2018-06-29 | Gilead Calistoga Llc | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS |
CN105658648B (zh) * | 2013-08-13 | 2020-03-17 | 加利福尼亚大学董事会 | 脱氧胞苷激酶抑制剂 |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
HUE051625T2 (hu) * | 2014-04-08 | 2021-03-29 | Incyte Corp | B-sejtes rosszindulatú daganatok kezelése JAK és PI3K inhibitorok kombinációjával |
MD20160138A2 (ro) * | 2014-05-27 | 2017-05-31 | Almirall S.A. | Combinaţie |
EA201692266A1 (ru) | 2014-06-13 | 2017-06-30 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
CA2952012A1 (en) | 2014-06-13 | 2015-12-17 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
EP3154962B1 (en) * | 2014-06-13 | 2019-08-07 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
CU24428B1 (es) | 2014-07-04 | 2019-06-04 | Lupin Ltd | Derivados de quinolizinona como inhibidores de pi3k |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
AU2015341186B2 (en) * | 2014-11-01 | 2019-11-14 | Fochon Biosciences, Ltd. | Certain protein kinase inhibitors |
EP3225618B1 (en) | 2014-11-26 | 2020-05-06 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
CN105712998B (zh) * | 2014-12-05 | 2019-12-13 | 上海润诺生物科技有限公司 | 氮杂吲哚类衍生物、其制备方法及其在医药上的应用 |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
US20190099404A1 (en) * | 2016-03-16 | 2019-04-04 | Zeno Royalties & Milestones, LLC | Analgesic compounds |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11083199B2 (en) | 2017-01-10 | 2021-08-10 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
CN107383004B (zh) * | 2017-07-05 | 2020-04-17 | 浙江大学 | 2-氨基咪唑并吡啶类衍生物及制备和应用 |
KR20200134203A (ko) * | 2017-08-21 | 2020-12-01 | 나비젠, 인코포레이티드 | Arf6 억제제 및 관련 방법 |
PE20210340A1 (es) * | 2017-09-15 | 2021-02-22 | Aduro Biotech Inc | Compuestos que contienen pirazolopirimidinona y sus usos |
US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
WO2020007698A1 (en) * | 2018-07-06 | 2020-01-09 | Leo Pharma A/S | Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof |
US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
WO2021010492A1 (en) * | 2019-07-17 | 2021-01-21 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
CN111346095B (zh) * | 2020-03-14 | 2021-06-08 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 用于治疗神经外科术后头痛的药物制剂 |
TW202208380A (zh) * | 2020-05-16 | 2022-03-01 | 大陸商重慶復創醫藥研究有限公司 | 作為激酶抑制劑的化合物 |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
US5200416A (en) * | 1980-05-12 | 1993-04-06 | Usv Pharmaceutical Corporation | Cyclic amides |
CY1492A (en) | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
ATE164525T1 (de) | 1990-09-26 | 1998-04-15 | Pharmachemie Bv | Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer |
GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
MY115140A (en) | 1992-12-18 | 2003-04-30 | Schering Corp | Inhaler for powdered medications |
NZ306280A (en) | 1995-04-14 | 1999-07-29 | Glaxo Wellcome Inc | Metered dose inhaler for salmeterol |
CA2378713C (en) | 1995-06-21 | 2003-08-12 | Asta Medica Aktiengesellschaft | Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
KR100785363B1 (ko) | 2000-04-25 | 2007-12-18 | 이코스 코포레이션 | 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제 |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
EP1685124A1 (en) | 2003-11-10 | 2006-08-02 | MERCK SHARP & DOHME LTD. | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
RU2413544C2 (ru) | 2004-07-16 | 2011-03-10 | Алмиралл, С.А. | Ингалятор и картридж для лекарственного порошкового препарата и способ работы ингалятора |
ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
NZ565749A (en) * | 2005-08-26 | 2010-12-24 | Serono Lab | Pyrazine derivatives and use as PI3K inhibitors |
ES2296516B1 (es) | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2302447B1 (es) | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
ES2320961B1 (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. |
EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2210615A1 (en) | 2009-01-21 | 2010-07-28 | Almirall, S.A. | Combinations comprising methotrexate and DHODH inhibitors |
EA019499B1 (ru) * | 2009-03-24 | 2014-04-30 | ГИЛИЭД КАЛИСТОГА ЭлЭлСи | Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения |
AU2010266064A1 (en) | 2009-06-25 | 2012-01-19 | Amgen Inc. | 4H - pyrido [1, 2 - a] pyrimidin - 4 - one derivatives as PI3 K inhibitors |
WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
-
2011
- 2011-04-29 EP EP11382124A patent/EP2518070A1/en not_active Withdrawn
-
2012
- 2012-04-20 TW TW101114160A patent/TWI535720B/zh not_active IP Right Cessation
- 2012-04-25 TW TW101114743A patent/TW201242967A/zh unknown
- 2012-04-26 HU HUE12717685A patent/HUE026041T2/en unknown
- 2012-04-26 AU AU2012247491A patent/AU2012247491B2/en not_active Ceased
- 2012-04-26 MY MYPI2013702039A patent/MY171553A/en unknown
- 2012-04-26 DK DK12717685.7T patent/DK2702061T3/en active
- 2012-04-26 SI SI201230347T patent/SI2702061T1/sl unknown
- 2012-04-26 KR KR1020137028410A patent/KR20140021622A/ko active IP Right Grant
- 2012-04-26 JP JP2014506869A patent/JP5903160B2/ja not_active Expired - Fee Related
- 2012-04-26 EA EA201301209A patent/EA024350B1/ru not_active IP Right Cessation
- 2012-04-26 SG SG2013074257A patent/SG194084A1/en unknown
- 2012-04-26 CN CN201280032781.1A patent/CN103649089B/zh not_active Expired - Fee Related
- 2012-04-26 WO PCT/EP2012/057671 patent/WO2012146666A1/en active Application Filing
- 2012-04-26 RS RS20150627A patent/RS54270B1/en unknown
- 2012-04-26 EP EP12717685.7A patent/EP2702061B9/en active Active
- 2012-04-26 ME MEP-2015-170A patent/ME02210B/me unknown
- 2012-04-26 PE PE2013002204A patent/PE20141193A1/es not_active Application Discontinuation
- 2012-04-26 ES ES12717685.7T patent/ES2545853T3/es active Active
- 2012-04-26 PL PL12717685T patent/PL2702061T3/pl unknown
- 2012-04-26 CA CA2826197A patent/CA2826197A1/en not_active Abandoned
- 2012-04-26 PT PT127176857T patent/PT2702061E/pt unknown
- 2012-04-26 BR BR112013023876A patent/BR112013023876A2/pt not_active IP Right Cessation
- 2012-04-26 US US14/114,541 patent/US9340547B2/en not_active Expired - Fee Related
- 2012-04-26 UA UAA201313706A patent/UA111197C2/uk unknown
- 2012-04-26 MX MX2013011781A patent/MX336214B/es unknown
- 2012-04-27 AR ARP120101485A patent/AR086144A1/es unknown
- 2012-05-02 UY UY0001034051A patent/UY34051A/es unknown
-
2013
- 2013-07-24 ZA ZA2013/05612A patent/ZA201305612B/en unknown
- 2013-08-01 IL IL227764A patent/IL227764A/en not_active IP Right Cessation
- 2013-10-15 CO CO13244188A patent/CO6801747A2/es not_active Application Discontinuation
- 2013-10-23 CR CR20130543A patent/CR20130543A/es unknown
- 2013-10-24 CL CL2013003073A patent/CL2013003073A1/es unknown
- 2013-10-28 GT GT201300266A patent/GT201300266A/es unknown
-
2014
- 2014-09-03 HK HK14108933.7A patent/HK1195552A1/zh not_active IP Right Cessation
-
2015
- 2015-10-29 SM SM201500270T patent/SMT201500270B/it unknown
- 2015-10-29 CY CY20151100967T patent/CY1116871T1/el unknown
- 2015-10-29 HR HRP20151153TT patent/HRP20151153T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL284539A (en) | Heterocycloamines as PI3K inhibitors | |
HK1195552A1 (zh) | 作為 抑制劑的吡咯並三嗪酮衍生物 | |
HK1211027A1 (zh) | 作為 抑制劑的吡咯並三嗪酮 | |
ZA201306296B (en) | Amino-quinolines as kinase inhibitors | |
IL228949A0 (en) | History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors | |
HK1210771A1 (zh) | 氮雜吲哚衍生物 | |
EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190428 |